Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amphastar Pharmaceuticals (AMPH – Research Report), Atara Biotherapeutics (ATRA – Research Report) and Tempest Therapeutics (TPST – Research Report).
Amphastar Pharmaceuticals (AMPH)
Needham analyst Serge Belanger maintained a Hold rating on Amphastar Pharmaceuticals today. The company’s shares closed last Wednesday at $45.42.
According to TipRanks.com, Belanger ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Amphastar Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $55.00.
See the top stocks recommended by analysts >>
Atara Biotherapeutics (ATRA)
Atara Biotherapeutics received a Hold rating from H.C. Wainwright analyst Robert Burns today. The company’s shares closed last Wednesday at $1.21, close to its 52-week low of $1.17.
According to TipRanks.com, Burns is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Atara Biotherapeutics has an analyst consensus of Hold, with a price target consensus of $5.84, representing a 332.6% upside. In a report released today, Mizuho Securities also downgraded the stock to Hold with a $1.00 price target.
Tempest Therapeutics (TPST)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Tempest Therapeutics today and set a price target of $47.00. The company’s shares closed last Wednesday at $2.82.
According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Tempest Therapeutics is a Moderate Buy with an average price target of $47.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AMPH:
